These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 34298557)

  • 41. The LDLR c.501C>A is a disease-causing variant in familial hypercholesterolemia.
    Hu H; Chen R; Hu Y; Wang J; Lin S; Chen X
    Lipids Health Dis; 2021 Sep; 20(1):101. PubMed ID: 34511120
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Improvement of Definite Diagnosis of Familial Hypercholesterolemia Using an Expanding Genetic Analysis.
    Cao YX; Sun D; Liu HH; Jin JL; Li S; Guo YL; Wu NQ; Zhu CG; Liu G; Dong Q; Sun J; Chen XH; Li JJ
    JACC Asia; 2021 Jun; 1(1):82-89. PubMed ID: 36338372
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Establishing the Mutational Spectrum of Hungarian Patients with Familial Hypercholesterolemia.
    Madar L; Juhász L; Szűcs Z; Kerkovits L; Harangi M; Balogh I
    Genes (Basel); 2022 Jan; 13(1):. PubMed ID: 35052492
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genetic Analysis in a Taiwanese Cohort of 750 Index Patients with Clinically Diagnosed Familial Hypercholesterolemia.
    Huang CC; Niu DM; Charng MJ
    J Atheroscler Thromb; 2022 May; 29(5):639-653. PubMed ID: 33994402
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients.
    Slimani A; Jelassi A; Jguirim I; Najah M; Rebhi L; Omezzine A; Maatouk F; Hamda KB; Kacem M; Rabès JP; Abifadel M; Boileau C; Rouis M; Slimane MN; Varret M
    Atherosclerosis; 2012 May; 222(1):158-66. PubMed ID: 22417841
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diagnostic yield of sequencing familial hypercholesterolemia genes in individuals with primary hypercholesterolemia.
    Lamiquiz-Moneo I; Civeira F; Mateo-Gallego R; Laclaustra M; Moreno-Franco B; Tejedor MT; Palacios L; Martín C; Cenarro A
    Rev Esp Cardiol (Engl Ed); 2021 Aug; 74(8):664-673. PubMed ID: 32660911
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The impact of gene variants on the thickness and softness of the Achilles tendon in familial hypercholesterolemia.
    Michikura M; Hori M; Ogura M; Hosoda K; Harada-Shiba M
    Atherosclerosis; 2022 Oct; 358():41-46. PubMed ID: 36087353
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Novel PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Variants in Patients With Familial Hypercholesterolemia From Cape Town.
    Huijgen R; Blom DJ; Hartgers ML; Chemello K; Benito-Vicente A; Uribe KB; Behardien Z; Blackhurst DM; Brice BC; Defesche JC; de Jong AG; Jooste RJ; Solomon GAE; Wolmarans KH; Hovingh GK; Martin C; Lambert G; Marais AD
    Arterioscler Thromb Vasc Biol; 2021 Feb; 41(2):934-943. PubMed ID: 33147992
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In silico analysis of upstream variants in Brazilian patients with Familial hypercholesterolemia.
    de Araújo JNG; de Oliveira VF; Borges JB; Dagli-Hernandez C; Marçal EDSR; Freitas RCC; Bastos GM; Gonçalves RM; Faludi AA; Jannes CE; Pereira ADC; Hirata RDC; Hirata MH; Luchessi AD; Silbiger VN
    Gene; 2023 Jan; 849():146908. PubMed ID: 36167182
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Unusual genetic variants associated with hypercholesterolemia in Argentina.
    Corral P; Geller AS; Polisecki EY; Lopez GI; Bañares VG; Cacciagiu L; Berg G; Hegele RA; Schaefer EJ; Schreier LE
    Atherosclerosis; 2018 Oct; 277():256-261. PubMed ID: 30270055
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Loss-of-function mutation of PCSK9 as a protective factor in the clinical expression of familial hypercholesterolemia: A case report.
    Bayona A; Arrieta F; Rodríguez-Jiménez C; Cerrato F; Rodríguez-Nóvoa S; Fernández-Lucas M; Gómez-Coronado D; Mata P
    Medicine (Baltimore); 2020 Aug; 99(34):e21754. PubMed ID: 32846800
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries.
    Futema M; Ramaswami U; Tichy L; Bogsrud MP; Holven KB; Roeters van Lennep J; Wiegman A; Descamps OS; De Leener A; Fastre E; Vrablik M; Freiberger T; Esterbauer H; Dieplinger H; Greber-Platzer S; Medeiros AM; Bourbon M; Mollaki V; Drogari E; Humphries SE
    Atherosclerosis; 2021 Feb; 319():108-117. PubMed ID: 33508743
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of familial hypercholesterolemia-associated genes on the phenotype of premature myocardial infarction.
    Lee C; Cui Y; Song J; Li S; Zhang F; Wu M; Li L; Hu D; Chen H
    Lipids Health Dis; 2019 Apr; 18(1):95. PubMed ID: 30971288
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia.
    Defesche JC; Stefanutti C; Langslet G; Hopkins PN; Seiz W; Baccara-Dinet MT; Hamon SC; Banerjee P; Kastelein JJP
    J Clin Lipidol; 2017; 11(6):1338-1346.e7. PubMed ID: 28964736
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia.
    Rubba P; Gentile M; Marotta G; Iannuzzi A; Sodano M; De Simone B; Jossa F; Iannuzzo G; Giacobbe C; Di Taranto MD; Fortunato G
    Eur J Prev Cardiol; 2017 Jul; 24(10):1051-1059. PubMed ID: 28353356
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The study of familial hypercholesterolemia in Italy: A narrative review.
    Bertolini S; Pisciotta L; Fasano T; Rabacchi C; Calandra S
    Atheroscler Suppl; 2017 Oct; 29():1-10. PubMed ID: 28965614
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Founder effects facilitate the use of a genotyping-based approach to molecular diagnosis in Swedish patients with familial hypercholesterolaemia.
    Benedek P; Jiao H; Duvefelt K; Skoog T; Linde M; Kiviluoma P; Kere J; Eriksson M; Angelin B
    J Intern Med; 2021 Aug; 290(2):404-415. PubMed ID: 33955087
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phenotypic variability in 4 homozygous familial hypercholesterolemia siblings compound heterozygous for LDLR mutations.
    Rabacchi C; Bigazzi F; Puntoni M; Sbrana F; Sampietro T; Tarugi P; Bertolini S; Calandra S
    J Clin Lipidol; 2016; 10(4):944-952.e1. PubMed ID: 27578127
    [TBL] [Abstract][Full Text] [Related]  

  • 59. APOE p.Leu167del mutation in familial hypercholesterolemia.
    Awan Z; Choi HY; Stitziel N; Ruel I; Bamimore MA; Husa R; Gagnon MH; Wang RH; Peloso GM; Hegele RA; Seidah NG; Kathiresan S; Genest J
    Atherosclerosis; 2013 Dec; 231(2):218-22. PubMed ID: 24267230
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.
    Lambert G; Petrides F; Chatelais M; Blom DJ; Choque B; Tabet F; Wong G; Rye KA; Hooper AJ; Burnett JR; Barter PJ; Marais AD
    J Am Coll Cardiol; 2014 Jun; 63(22):2365-73. PubMed ID: 24632287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.